STIMULATE INNOVATION AND GROWTH THROUGH STRATEGIC ALLIANCES
Pharmaceutical companies are increasingly having to forge partnerships, mainly due to the rising cost of research and development, the increase in the bargaining power of buyers, more and more restrictive regulations, or the evolution towards an integrated care offer.
Pharmaceutical companies are increasingly having to forge partnerships, mainly due to the rising cost of research and development, the increase in the bargaining power of buyers, more and more restrictive regulations, or the evolution towards an integrated care offer. While strategic alliances may seem time-consuming to implement and complex to manage, they nevertheless offer an interesting “benefit-risk ratio” that explains their growing use. In this article, we will recall the principles of a strategic alliance. We will then present their current uses in the pharmaceutical industry and identify the associated key success factors.
Only logged in customers who have purchased this product may leave a review.
You may also like
The key promise of the Industry 4.0 concept is as striking as it is fascinating: we are about to witness a new industrial revolution, fueled by the advancement of digital technologies. The fusion of the physical and the virtual world into cyberphysical systems will have a disruptive impact on every business domain of manufacturing companies.
Industry 4.0 – Sharpening the Picture beyond the Hype$0.00 Capgemini
The financial crisis and its effect on the real economy initiated a debate at the beginning of 2009 on the need to change the financial industry regulation in order to prevent new crises, mitigate systemic risk and develop a balanced framework for competition.
Capital Adequacy for credit risk: A practical exercise$0.00 Management Solutions
Artificial intelligence (AI) has the potential to transform the pharmaceutical industry. Each of the major pharma players is investing in the technology at some level, and there are a growing number of applications that address target and drug discovery, preclinical and clinical development, and postapproval activities.
Artificial Intelligence in Life Sciences$0.00 LEK
Trouble with Conavigo
Want to refine your results?
Help with Sourcing
Need help with your Sourcing?